Haircloning for hair loss is unlikely to be available or affordable in the next 10 years. Current treatments like Minoxidil, finasteride, and RU58841 are still the main options, with skepticism about new advancements.
A recent discovery in haircloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.
The conversation discusses hair loss treatments, focusing on Tsuji'shaircloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.
Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for haircloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.
Haircloning is seen as a distant and potentially less relevant solution for hair loss due to its high cost, invasiveness, and the advancement of other treatments like Minoxidil and finasteride. Many believe that by the time haircloning becomes viable, other less invasive and more effective treatments will be available.
2 citations
,
March 2013 in “Hair transplant forum international”
This article discusses the concept of haircloning through cultured follicular cell implantation but provides no new experimental results; it highlights ongoing interest among hair restoration professionals and the public.
This review discusses recent advancements in hair follicle regeneration technologies, including the authors' own development of functional hair regeneration through bioengineered follicle germ transplantation, but reports no new clinical results.
This review discusses the strategies and progress in developing bioengineered organ replacement therapies but reports no new clinical results, highlighting the potential for future regenerative solutions.